<?xml version="1.0" encoding="UTF-8"?>
<results title="zoonosis">
 <result pre="COVID-19, SARS emerged as an epidemic in 2003, followed by" exact="Middle East respiratory syndrome" post="(MERS) in 2012, both caused by a novel coronavirus"/>
 <result pre="the characteristic IgG and IgM production. At the onset of" exact="SARS-CoV infection," post="B cells elicit an early response against the N"/>
 <result pre="(69). Although there is no clear evidence regarding ADE in" exact="SARS-CoV-2 infection," post="it is still necessary to consider all of the"/>
 <result pre="whereas the HLA-DRB1*03, HLA-A*02, and HLA-Cw*15 haplotypes are protected from" exact="SARS-CoV infection" post="(74). Similarly, HLA-DRB1*11 and HLA-DQB1*02 were found to be"/>
 <result pre="77). So far, HLA association is not very well-identified for" exact="SARS-CoV-2 infection," post="and this could be crucial for the prevention and"/>
 <result pre="in SARS patients (61). In a large cohort study during" exact="SARS-CoV infection," post="S protein was the only immuno-dominant epitope for CD8+"/>
 <result pre="prospective subunit vaccine for stimulating a strong T-cell response in" exact="COVID 19" post="patients (84). In a recent study, samples from 20"/>
 <result pre="elevated chemokines (IP-10, CCL2/MCP1, CXCL1, CXCL5) were also detected in" exact="SARS-CoV-2 infection" post="(96â€&quot;99). In children, the increased inflammatory markers include IL-6,"/>
 <result pre="ISRE promoters (109â€&quot;111) (Figure 3). A new investigation revealed that" exact="SARS-CoV-2 infection" post="leads to an overall decrease in the transcription of"/>
 <result pre="COVID-19 severity (112). In addition to reduction in T cells," exact="SARS-CoV-2 infection" post="also enhances the exhaustion of effector T cells, decreasing"/>
 <result pre="producing IFN-Î³, which further contributes to conferring protective immunity against" exact="SARS-CoV-2 infection" post="(184). Recently, a monoclonal antibody (47D11) has been identified"/>
 <result pre="determine the efficacy of these antibodies in the treatment of" exact="SARS-CoV-2 infection." post="Clinical trial ChiCTR2000029765 with tocilizumab, a monoclonal humanized antibody"/>
 <result pre="(2016) 14:523â€&quot;34. 10.1038/nrmicro.2016.8127344959 5.VerityROkellLCDorigattiIWinskillPWhittakerCImaiNet al.. Estimates of the severity of" exact="coronavirus disease 2019" post=": a model-based analysis. Lancet Infect Dis. (2020) 3099:1â€&quot;9."/>
 <result pre="(2005) 79:5288â€&quot;95. 10.1128/jvi.79.9.5288-5295.200515827143 38.PerrierABonninADesmaretsLDanneelsAGoffardARouillÃ©Yet al.. The C-terminal domain of the" exact="MERS coronavirus" post="M protein contains a trans-Golgi network localization signal. J"/>
 <result pre="16:240â€&quot;6. 10.1007/s12519-020-00345-532026148 51.ShekerdemianLSMahmoodNRWolfeKKRiggsBJRossCEMcKiernanCAet al.. Characteristics and outcomes of children with" exact="coronavirus disease 2019" post="(COVID-19) infection admitted to US and canadian pediatric intensive"/>
 <result pre="responses. Vaccine. (2007) 25:6981â€&quot;91. 10.1016/j.vaccine.2007.06.04717709158 82.ZhaoJAlshukairiANBaharoonSAAhmedWABokhariAANehdiAMet al.. Recovery from the" exact="Middle East respiratory syndrome" post="is associated with antibody and T cell responses. Sci"/>
 <result pre="cytokines and suppression of innate antiviral response by the novel" exact="Middle East respiratory syndrome" post="coronavirus: implications for pathogenesis and treatment. J Gen Virol."/>
 <result pre="91.ChannappanavarRFehrARZhengJWohlford-LenaneCAbrahanteJEMackMet al.. IFN-I response timing relative to virus replication determines" exact="MERS coronavirus" post="infection outcomes. J Clin Invest. (2019) 129:3625â€&quot;39. 10.1172/JCI12636331355779 92.NgDLAl"/>
 <result pre="Reduction and functional exhaustion of T cells in patients with" exact="coronavirus disease 2019" post="(COVID-19). Front Immunol. (2020) 2019:1â€&quot;14. 10.3389/fimmu.2020.0082732425950 95.ZheXuLeiShiYijinWangJiyuanZhangLeiHuangChaoZhanget al.. Pathological"/>
 <result pre="Rev. (2020) 7:1â€&quot;5. 10.1093/nsr/nwaa041 98.WenZhangYanZhaoFengchunZhangQianWangTaishengLiZhengyinLiuet al.. Anti-inflammation treatment of severe" exact="coronavirus disease 2019" post="(COVID-19): from the perspective of clinical immunologists from China."/>
 <result pre="proteins M, ORF 4a, ORF 4b, and ORF 5 of" exact="Middle East respiratory syndrome" post="coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell. (2013)"/>
 <result pre="reading frame 3b protein. J Virol. (2009) 83:6631â€&quot;40. 10.1128/jvi.00367-0919403678 110.Kopecky-BrombergSAMartinez-SobridoLFriemanMBaricRAPaleseP." exact="Severe acute respiratory syndrome" post="coronavirus open reading frame (ORF) 3b, ORF 6, and"/>
 <result pre="Immunity. (2016) 44:1379â€&quot;91. 10.1016/j.immuni.2016.05.00627287409 122.SunSChenQGuHYangGWangYHuangXet al.. A mouse model of" exact="SARS-CoV-2 infection" post="and pathogenesis. Cell Host Microbe. (2020) 28:124â€&quot;33.e4. 10.1016/j.chom.2020.05.02032485164 123.ZumlaAChanJFWAzharEIHuiDSCYuenKY."/>
 <result pre="(2020) 5883:1â€&quot;21. 10.1126/scitranslmed.abb588332253226 137.RichardsonPGriffinITuckerCSmithDOechsleOPhelanAet al.. Baricitinib as potential treatment for" exact="2019-nCoV acute respiratory disease." post="Lancet. (2020) 395:e30â€&quot;e31. 10.1016/S0140-6736(20)30304-432032529 138.SheahanTPSimsACLeistSRSchÃ¤ferAWonJBrownAJet al.. Comparative therapeutic efficacy"/>
 <result pre="30:269â€&quot;71. 10.1038/s41422-020-0282-032020029 142.OmraniASSaadMMBaigKBahloulAAbdul-MatinMAlaidaroosAYet al.. Ribavirin and interferon alfa-2a for severe" exact="Middle East respiratory syndrome" post="coronavirus infection: a retrospective cohort study. Lancet Infect Dis."/>
 <result pre="Med. (2020) 382:929â€&quot;36. 10.1056/NEJMoa200119132004427 153.BeigelJHTomashekKMDoddLEMehtaAKZingmanBSKalilACet al.Remdesivir for the Treatment of" exact="Covid-19" post="- Preliminary Report. N Engl J Med. (2020) NEJMoa2007764."/>
 <result pre="the sera of convalescent cases. Virology. (2004) 324:251â€&quot;6. 10.1016/j.virol.2004.04.01715207612 174.Tsunetsugu-YokotaYOhnishiKTakemoriT." exact="Severe acute respiratory syndrome" post="(SARS) coronavirus: application of monoclonal antibodies and development of"/>
 <result pre="(2020) 52:1â€&quot;7. 10.1016/j.immuni.2020.04.02331940266 185.WangCLiWDrabekDOkbaNMAHaperenRVan OsterhausADMEet al.A human monoclonal antibody blocking" exact="SARS-CoV-2 infection." post="Nat Commun. (2020) 11:1â€&quot;6. 10.1038/s41467-020-16256-y31911652 186.WuYLiCXiaSXiaolongTKongYWangZet al.. Identification of"/>
 <result pre="LimitedMesoblast To Evaluate Anti-Inflammatory Cell Therapy Remestemcel-L for Treatment of" exact="Covid-19" post="Lung Disease. Melbourne; New York, NY: ASX announcement (2020)."/>
</results>
